Press Releases

October 22, 2018 Lupin receives FDA approval for generic Triamcinolone Acetonide Ointment USP, 0.1%

October 19, 2018 Lupin’s Pithampur Unit-3 (Indore) Inspected by US FDA

October 19, 2018 Lupin Neurosciences Announces Positive CHMP Opinion for NaMuscla™ for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders

October 16, 2018 Survey Data Reveals the Need for Improved Communication Between Patients and Healthcare Providers About Bacterial Vaginosis (BV), the Most Common Gynecologic Infection in the U.S.

October 15, 2018 Lupin receives tentative FDA approval for generic Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg and 120 mg

October 13, 2018 Lupin Quarter II, FY2019 – Results

October 9, 2018 Lupin launches generic Clobetasol Propionate Ointment USP 0.05% in the US

October 4, 2018 Lupin launches generic Potassium Chloride Oral Solution USP, 20 mEq/15mL (10%) and 40 mEq/15 mL (20%)

September 18, 2018 Lupin appoints Alok Sonig as CEO – US Generics and Global Head – Generics R&D & Biosimilars